Heart Test Laboratories’ (HSCS) “Buy” Rating Reaffirmed at Maxim Group

Maxim Group reiterated their buy rating on shares of Heart Test Laboratories (NASDAQ:HSCS) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

Separately, Ascendiant Capital Markets reaffirmed a “buy” rating and set a $15.00 target price on shares of Heart Test Laboratories in a report on Monday, September 23rd.

Heart Test Laboratories Stock Performance

Shares of HSCS stock traded down $0.17 on Wednesday, hitting $3.59. 27,754 shares of the stock were exchanged, compared to its average volume of 130,911. Heart Test Laboratories has a one year low of $2.36 and a one year high of $18.50. The firm’s 50 day moving average is $3.24 and its two-hundred day moving average is $3.79. The firm has a market capitalization of $3.28 million, a PE ratio of -0.17 and a beta of 3.23. The company has a current ratio of 4.49, a quick ratio of 4.02 and a debt-to-equity ratio of 0.08.

Heart Test Laboratories (NASDAQ:HSCS) last released its quarterly earnings data on Monday, December 16th. The company reported ($2.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.30) by $0.03. During the same quarter in the previous year, the business earned ($15.92) earnings per share. Sell-side analysts expect that Heart Test Laboratories will post -9.82 earnings per share for the current fiscal year.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.